Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 clients • 8 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready
Prismatic Law Group, PLLC operates within the Biotechnology & Pharmaceuticals sector, handling 177 career applications. The firm has achieved a resolved allowance rate of 76.99 percent, which serves as a benchmark for its performance in this field. Prosecution typically requires 3.59 office actions per allowance, suggesting a rigorous examination process for these life sciences patents.
The firm currently manages 7 pending office actions. For clients in the Biotechnology & Pharmaceuticals space, the 76.99 percent allowance rate and the 177 career applications provide a clear view of the firm's historical footprint. The average of 3.59 office actions per allowance highlights the persistence required to navigate the USPTO in this technology area, ensuring that each application is thoroughly examined.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
| LEVERETT, MARY CHANG | 1 | 60.2% | +20.8% |
| MAHLUM, JONATHAN DAVIS | 1 | 51.4% | +25.6% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | WEDDINGTON, KEVIN E | 182d overdue |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | LEVERETT, MARY CHANG | 30d |
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | MAHLUM, JONATHAN DAVIS | 80d overdue |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | LEVERETT, MARY CHANG | 30d |
| 18835823 | DHODH INHIBITOR POLYMORPH | VALENROD, YEVGENY | — |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | MELCHIOR, JAMES RYLAND | — |
| 18258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | DONOGHUE, BRITTNEY ERIN | — |
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | — |
| 16621741 | NOVEL METHODS FOR THE GENERATION AND USE OF HUMAN INDUCED NEURAL BORDER STEM CELLS | MIANO, JOSEPH PAUL | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Aslan Pharmaceuticals | 2 |
| Numab Therapeutics AG | 2 |
| Roche | 1 |
| UMC UTRECHT HOLDING B.V. | 1 |
| Julius-Maximilians-Universität Würzburg | 1 |
| Hi-Stem Ggmbh | 1 |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1675 | 1 |
| 1642 | 1 |
| 1629 | 1 |
| 1687 | 1 |
| 1625 | 1 |
| 1631 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18835823 | DHODH INHIBITOR POLYMORPH | Aslan Pharmaceuticals Pte Ltd | VALENROD, YEVGENY | §112 | Non-Final OA | — | Pending | Aug 05, 2024 | |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | Numab Therapeutics AG | MELCHIOR, JAMES RYLAND | 1644 | §112DPOther | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | Numab Therapeutics AG | DONOGHUE, BRITTNEY ERIN | 1675 | §112DP | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18317385 | DUAL TARGETING | Hoffmann-La Roche, Inc. | MOSELEY II, NELSON B | 1642 | §102§112 | Non-Final OA | — | Pending | May 15, 2023 |
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | Aslan Pharmaceuticals Pte Ltd | WEDDINGTON, KEVIN E | 1629 | §101§102§103§112 | Non-Final OA | 182d overdue | Pending | Mar 16, 2023 |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | UMC Utrecht Holding B.V. | LEVERETT, MARY CHANG | 1687 | §101§103§112 | Non-Final OA | 30d | Pending | Oct 05, 2022 |
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | Julius-Maximilians-Universitaet Wuerzburg | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 80d overdue | Pending | Sep 12, 2022 |
| 16621741 | NOVEL METHODS FOR THE GENERATION AND USE OF HUMAN INDUCED NEURAL BORDER STEM CELLS | Hi-Stem Ggmbh | MIANO, JOSEPH PAUL | 1631 | §103 | Non-Final OA | — | Pending | Dec 12, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial